Best Lung Cancer Awareness Podcasts (2025)

1
Jeri Gill | Ms. Senior World Louisiana and Living Kidney Donor 29:17

Play Pause

3h ago29:17

29:17

Show Notes: On this episode we shine a spotlight on an incredible woman whose story combines generosity and advocacy with a touch of pageant sparkle. Jeri Gill, an altruistic living kidney donor, was recently crowned 2025 Ms. Senior World Louisiana in the 60’s age category. Jeri's platform is organ donation, and she uses her voice to champion the g…

1
S14 Ep24: FDA Approval Insights: Maintenance Lurbinectedin Plus Atezolizumab for ES-SCLC: With Anne Chiang, MD, PhD; and Stephen Liu, MD 12:45

2h ago12:45

12:45

In today’s episode, we had the pleasure of speaking with Anne Chiang, MD, PhD, and Stephen Liu, MD, about the FDA approval of lurbinectedin (Zepzelca) plus atezolizumab (Tecentriq) or atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza) as maintenance treatment for adult patients with extensive-stage small cell lung cancer (ES-SCLC) whose diseas…

1
S14 Ep23: Early Biomarker Testing Optimizes Tepotinib Use in NSCLC With MET Exon 14 Skipping Mutations: With Stephen Liu, MD 9:48

23h ago9:48

9:48

In today’s episode, we had the pleasure of speaking with Stephen Liu, MD, about the use of tepotinib (Tepmetko) in patients with metastatic non–small cell lung cancer (NSCLC) harboring MET exon 14 skipping alterations. Dr Liu is an associate professor of medicine at Georgetown University, as well as the director of Thoracic Oncology and head of Dev…

1
S14 Ep22: Expanding JAK Inhibitor Use Offers Increased Treatment Options for Cytopenic Myelofibrosis: With Andrew Kuykendall, MD 11:11

18h ago11:11

11:11

In today’s episode, we had the pleasure of speaking with Andrew Kuykendall, MD, who gave an overview of the myelofibrosis treatment paradigm. Dr Kuykendall is an assistant member in the Department of Malignant Hematology at Moffitt Cancer Center in Tampa, Florida. In our exclusive interview, Dr Kuykendall discussed the prevalence of patients with m…

1
S14 Ep21: Early CAR T-Cell Therapy Data Highlight Therapeutic Potential and Emerging Challenges in GI Cancers: With Kohei Shitara, MD 8:48

5d ago8:48

8:48

In our exclusive interview, Dr Shitara discussed preliminary efficacy data with CAR T-cell therapy in gastrointestinal cancers; highlighted challenges related to durability of response, patient selection, and manufacturing logistics with these therapies; and outlined ongoing biomarker analyses exploring tumor microenvironment factors influencing re…

1
S14 Ep20: The Evolving Role of Noncovalent BTK Inhibition Informs CLL Treatment Selection: With Asad Dean, MD 16:19

6d ago16:19

16:19

In today’s episode, we had the pleasure of speaking with Asad Dean, MD, about treatment selection for patients with chronic lymphocytic leukemia (CLL) in the second-line setting. Dr Dean is a physician at the Texas Oncology-Fort Worth Cancer Center. In our exclusive interview, Dr Dean discussed the roles of covalent BTK inhibitors and BCL-2 inhibit…

1
S14 Ep19: Zidesamtinib Is Associated With CNS Activity and Low Rates of Neurologic AEs in Pretreated ROS1+ NSCLC: With Alexander Drilon, MD 8:28

12d ago8:28

8:28

In today’s episode, we had the pleasure of speaking with Alexander Drilon, MD, about the phase 1/2 ARROS-1 trial (NCT05118789) investigating zidesamtinib (NVL-520) in TKI-pretreated patients with advanced ROS1-positive non–small cell lung cancer (NSCLC). Dr Drilon is chief of the Early Drug Development Service at Memorial Sloan Kettering Cancer Cen…

1
S14 Ep18: Patient Characteristics and Disease Factors Guide the Use of Dostarlimab in Recurrent Endometrial Cancer: With Dana M. Chase, MD 16:13

13d ago16:13

16:13

In our exclusive interview, Dr Chase discussed the management of recurrent endometrial cancer, emphasizing the importance of biomarker profiles and previous therapies. For first recurrences, she explained that carboplatin and paclitaxel with pembrolizumab (Keytruda) or dostarlimab-gxly (Jemperli) is recommended for patients with mismatch repair–def…

1
S14 Ep17: Expert Guidance on Frequently Asked Questions Regarding the Use of ADCs in TNBC 18:28

14d ago18:28

18:28

In this podcast, experts Aditya Bardia, MD, MPH, FASCO, Erika P. Hamilton, MD, and Virginia Kaklamani, MD, DSc, discuss frequently asked questions regarding the use of antibody-drug conjugates (ADCs) in triple-negative breast cancer (TNBC).By OncLive® On Air

1
S14 Ep16: Establishing the Rationale for ADC and ICI Combinations in TNBC 18:30

14d ago18:30

18:30

In this podcast, experts Virginia Kaklamani, MD, DSc, and Tiffany A. Traina, MD, FASCO, discuss the rationale for and data to support combining TROP2-targeting antibody-drug conjugates (ADCs) with immune checkpoint inhibitors (ICIs) to treat triple-negative breast cancer (TNBC).By OncLive® On Air

1
Deep Into Healthcare & Leadership With Coach T 25:16

17d ago25:16

25:16

Send us a text What does it take to help patients breathe while also helping students find their voice in healthcare? In this episode of The Surgeon Soneesh Show, I sit down with Coach Nate Thomas, RRT, a dedicated respiratory therapist and Georgia HOSA state officer coach, whose impact reaches far beyond the hospital. Coach T has been on the front…

1
S14 Ep15: Cohort Analysis Shows Importance of Early-Onset CRC Awareness and Investigation: With Evelyn Y. Wong, MD 7:02

15d ago7:02

7:02

In today’s episode, we had the pleasure of speaking with Evelyn Y. Wong, MD, about the growing challenge of early-onset colorectal cancer (CRC) and the insights from a recent cohort analysis conducted in Singapore. Dr Wong is a consultant medical oncologist specializing in gastrointestinal cancers at the National Cancer Centre Singapore. In our exc…

1
S14 Ep14: Expert Roundtable and Panel Discussions: Current and Future Landscape of TNBC 18:17

15d ago18:17

18:17

In this podcast, experts Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; and Tiffany A. Traina, MD, FASCO; discuss navigating between currently available therapies for patients with triple-negative breast cancer (TNBC). They also discuss the potential ramifications of ongoing clinical trials on future treatment paradigms.…

1
S14 Ep13: Dissecting Clinical Trial and Real-World Data for ADCs in TNBC 20:08

15d ago20:08

20:08

In this podcast, experts Filipa Lynce, MD, and Rita Nanda, MD, discuss recent clinical trial and real-world data for antibody-drug conjugates (ADCs) used to treat triple-negative breast cancer (TNBC).By OncLive® On Air

1
A Conversation About Entrepreneurship With Mahir Laul 26:55

16d ago26:55

26:55

Send us a text In this episode, I sit down with Mahir Laul, an 18-year-old entrepreneur & influencer with over 20K followers who's the Founder & CEO of Velric, an AI-powered performance platform, while simultaneously working in strategy at Laul Global Ventures across 30+ countries. We dive into the realities of building a tech company as a teenager…

1
S14 Ep12: Evaluating the Latest Data and Ongoing Trials for Novel ADC Approaches in TNBC 17:00

18d ago17:00

17:00

In this podcast, experts Aditya Bardia, MD, MPH, FASCO; and Erika P. Hamilton, MD, discuss recent efficacy and safety data of TROP2-targeted antibody-drug conjugate (ADC) plus immune checkpoint inhibitor combinations for advanced triple-negative breast cancer (TNBC).By OncLive® On Air

1
S14 Ep11: Breaking Down the Rationale for Targeting TROP2 in TNBC 14:48

18d ago14:48

14:48

In this podcast, experts Filipa Lynce, MD, and Rita Nanda, MD, discuss unmet needs in triple-negative breast cancer (TNBC) and the rationale for using TROP2-targeting antibody-drug conjugates (ADCs) in this disease.By OncLive® On Air

1
S14 Ep10: Patient Characteristics and Care Team Collaboration Influence Treatment Decision-Making in CLL: With John N. Allan, MD; and Melissa Rubianes 15:30

19d ago15:30

15:30

In today’s episode, we had the pleasure of speaking with John N. Allan, MD, and Melissa Rubianes about factors that influence treatment decision-making in chronic lymphocytic leukemia (CLL). Allan is an associate professor of clinical medicine and a member of the lymphoma faculty in the Division of Hematology and Medical Oncology, as well as a memb…

1
Gut Health & Beyond: A Conversation with Rishab Jain, Founder of Claisen 41:34

19d ago41:34

41:34

Send us a text In this episode, I sit down with Rishab Jain, Founder of Claisen, to explore the story behind this innovative startup. We dive into how Claisen came to life, the challenges of building a company from the ground up, and the lessons Rishab has learned along the way. From the early stages to future ambitions, this conversation offers in…

1
S14 Ep9: Tepotinib Efficacy and Safety Profiles Underscore the Importance of Biomarker-Directed Decision-Making in NSCLC: With Balazs Halmos, MD, MS 13:37

21d ago13:37

13:37

In today’s episode, we had the pleasure of speaking with Balazs Halmos, MD, MS, about the phase 2 VISION trial (NCT02864992) evaluating tepotinib (Tepmetko) in patients with MET exon 14 skipping mutation–positive non–small cell lung cancer (NSCLC). Dr Halmos is a professor in the Department of Oncology (Medical Oncology) and the Department of Medic…

1
S14 Ep8: Recent FDA Approvals and Ongoing Research Expand Treatment Options for Soft Tissue Sarcoma: With Samantha A. Armstrong, MD; and Karine Tawagi, MD 21:10

22d ago21:10

21:10

Two Onc Docs, hosted by Samantha A. Armstrong, MD, and Karine Tawagi, MD, is a podcast dedicated to providing current and future oncologists and hematologists with the knowledge they need to ace their boards and deliver quality patient care. Dr Armstrong is a hematologist/oncologist and assistant professor of clinical medicine at Indiana University…

1
Miss Louisiana's Teen Virginia Kirkpatrick 26:34

26d ago26:34

26:34

Show Notes: On this episode of The Gifted Life Podcast we welcome Miss Louisiana’s Teen 2025, Virginia Kirkpatrick. 17 year old Virginia is an impressive leader on every level, but what really stood out is her Community Service Initiative to educate and encourage registration as an organ and tissue donor, “Life After Mine: Your Choice, Their Chance…

1
S14 Ep7: Clinical Trial and Real-World Data With NALIRIFOX Shape the Future of Pancreatic Cancer Care: With Tara E. Seery, MD; Paul E. Oberstein, MD; and Priyadarshini Pathak, MBBS 15:30

26d ago15:30

15:30

In today’s episode, we passed the mic to Tara E. Seery, MD, who moderated an OncLive Insights discussion on the future of the pancreatic cancer treatment paradigm. Rounding out the discussion with additional expert perspectives were Paul E. Oberstein, MD, and Priyadarshini Pathak, MBBS. Seery is a medical oncologist at the Hoag Family Cancer Instit…

1
S14 Ep6: Advances in ctDNA Testing Guide Clinical Decision-Making in GI Cancer Management: With Scott Kopetz, MD, PhD, FACP 21:38

27d ago21:38

21:38

In today’s episode, we spoke with Scott Kopetz, MD, PhD, FACP, about the use of circulating tumor DNA (ctDNA) in patients with colorectal cancer (CRC). Dr Kopetz is the deputy chair for Translational Research and a professor in the Department of Gastrointestinal (GI) Medical Oncology in the Division of Cancer Medicine, as well as the leader of the …

1
S14 Ep5: Safety and Quality-of-Life Considerations Shape ADT Use in Prostate Cancer: With Tanya B. Dorff, MD 15:03

28d ago15:03

15:03

In today’s episode, supported by Sumitomo, we spoke with Tanya B. Dorff, MD, about the use of androgen deprivation therapy (ADT) in patients with prostate cancer. Dr Dorff is section chief of the Genitourinary Disease Program, as well as a professor in the Department of Medical Oncology & Therapeutics Research at City of Hope in Duarte, California.…

1
S14 Ep4: FDA Approval Insights: Dordaviprone in H3K27M-Mutated Diffuse Midline Glioma: With Patrick Y. Wen, MD 10:11

29d ago10:11

10:11

In today’s episode, supported by Chimerix, we spoke with Patrick Y. Wen, MD, about the FDA approval of dordaviprone (Modeyso) for the treatment of adult and pediatric patients at least 1 year of age with H3K27M-mutated diffuse midline glioma who have progressive disease following prior therapy. Dr Wen is the director of the Center for Neuro-Oncolog…

1
S14 Ep3: FDA Approval Insights: Taletrectinib in ROS1+ Advanced/Metastatic NSCLC: With Joel Neal, MD, PhD; and Christian Rolfo, MD, PhD 14:18

1M ago14:18

14:18

In today’s episode, supported by Nuvation Bio, we spoke with Joel Neal, MD, PhD, and Christian Rolfo, MD, PhD, about the FDA approval of taletrectinib (Ibtrozi) for the treatment of patients with locally advanced or metastatic, ROS1-positive non–small cell lung cancer (NSCLC). Dr Neal is a professor of medicine in the Division of Oncology at the St…

1
S14 Ep2: FDA Approval Insights: Zongertinib in HER2-Mutated NSCLC: With Ticiana Leal, MD, and Misako Nagasaka, MD, PhD 15:43

1M ago15:43

15:43

In today’s episode, supported by Boehringer Ingelheim, we spoke with Ticiana Leal, MD, and Misako Nagasaka, MD, PhD, about the FDA approval of zongertinib (Hernexeos) for previously treated patients with HER2 TKD–mutant advanced non–small cell lung cancer (NSCLC). Dr Leal is an associate professor and director of the Thoracic Medical Oncology Progr…

1
S14 Ep1: Obe-Cel Data Are Poised to Refine and Expand the ALL Treatment Paradigm: With Aaron Logan, MD, PhD; and Bijal Shah, MD, MS 39:51

1M ago39:51

39:51

In today’s episode, supported by Autolus, we spoke with Aaron Logan, MD, PhD, and Bijal Shah, MD, MS, about the evolving use of obecabtagene autoleucel (obe-cel; Aucatzyl) in the relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) treatment paradigm. Dr Logan is an associate professor of clinical medicine in the Division of Hematology/O…

1
S13 Ep50: SUPRAME Trial Propels the Development of TCR-Based Therapy in Cutaneous Melanoma: With Jason Luke, MD 7:17

1M ago7:17

7:17

In today’s episode, supported by Immatics, we spoke with Jason Luke, MD, about the development of the PRAME-directed T-cell receptor (TCR) T-cell therapy IMA203 in the ongoing phase 3 SUPRAME trial (NCT06743126) in patients with previously treated, unresectable or metastatic cutaneous melanoma. In our conversation, Dr Luke discussed the rationale f…

1
S13 Ep49: Distinguishing Pathway to Precision for c-Met and MET Alterations in NSCLC 24:55

1M ago24:55

24:55

In this podcast, experts Erminia Massarelli, MD, PhD, MS; Jorge J. Nieva, MD; Sandip Patel, MD; and Ignacio I. Wistuba, MD, discuss new therapies for patients with c-Met–overexpressing non–small cell lung cancer.By OncLive® On Air

1
S13 Ep48: Refining First-Line Immunotherapy Strategies in Hepatocellular Carcinoma: With Masatoshi Kudo, MD, PhD 7:21

1M ago7:21

7:21

In today’s episode, we spoke with Masatoshi Kudo, MD, about the evolving treatment landscape in hepatocellular carcinoma (HCC) and how recent comparative analyses are helping refine the use of first-line immunotherapy-based regimens. Dr Kudo is a professor and chairman in the Department of Gastroenterology and Hepatology at Kindai University Facult…

1
S13 Ep47: Multidisciplinary Collaboration Gives Forward Momentum to HER2 IHC Testing in NSCLC: With Ronan J. Kelly, MD, MBA, FASCO; and Michelle Shiller, DO, AP/CP, MGP 21:31

1M ago21:31

21:31

In today’s episode, supported by Daiichi-Sankyo, we spoke with Ronan J. Kelly, MD, MBA, FASCO; and Michelle Shiller, DO, AP/CP, MGP, about HER2 immunohistochemistry (IHC) testing in non–small cell lung cancer (NSCLC). Kelly is director of the Charles A. Sammons Cancer Center and chief science officer at Baylor University Medical Center in Dallas, T…

1
S13 Ep46: FDA Approval Insights: Linvoseltamab in Relapsed/Refractory Multiple Myeloma: With Nisha Joseph, MD; and Hans Lee, MD 12:38

1M ago12:38

12:38

In today’s episode, we spoke with Nisha Joseph, MD, and Hans Lee, MD, about the FDA's accelerated approval of linvoseltamab-gcpt (Lynozyfic) for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 4 or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD3…

1
S13 Ep45: Exploring NCCN Guideline Updates and Advancing Immunotherapy Strategies in Nasopharyngeal Carcinoma: With Neal S. Akhave, MD 10:36

2M ago10:36

10:36

In our conversation, Dr Akhave discussed the addition of toripalimab (Loqtorzi), a PD-1 inhibitor, to the NCCN Guidelines following its launch in the United States. Supported by data from the phase 3 JUPITER-02 trial (NCT03581786), toripalimab is now incorporated into frontline therapy for patients with recurrent metastatic or de novo metastatic Ep…

1
S13 Ep44: Frank’s Path to Advancing Hematology Through Innovation and Discovery: With Girindra Raval, MD; and David A. Frank, MD, PhD, FACP 40:56

2M ago40:56

40:56

In this episode, Raval welcomed David A. Frank, MD, PhD, FACP, who is director of the Division of Hematology and a professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine. He also serves as director of the Winship Innovation Initiative and as an advisor to the Morningside Center for Innovative and Affor…

1
S13 Ep43: Real-World Perspectives on mCRC and GI Neuroendocrine Neoplasms; With Rocío García-Carbonero, MD, PhD 11:33

2M ago11:33

11:33

In our conversation, Dr García-Carbonero discussed a subgroup analysis from the phase 3 FRESCO-2 trial (NCT04322539), which evaluated fruquintinib (Fruzaqla) in previously treated metastatic CRC (mCRC). She reviewed efficacy outcomes by metastatic site, including liver-only, lung-only, bone, and peritoneal disease. Fruquintinib demonstrated improve…

1
S13 Ep42: Endometrial (Uterine) Cancer 2025 UPDATE 12:23

2M ago12:23

12:23

In this episode, OncLive On Air® partnered with Two Onc Docs, Tawagi and Armstrong reviewed key principles in the diagnosis and management of uterine and endometrial cancers, incorporating updates in surgical approaches, adjuvant therapy selection, molecular testing, and the management of rare uterine sarcomas. The discussion outlined the epidemiol…

1
S13 Ep41: The European Approval of Mirdametinib Expands the Treatment Paradigm for NF1-Associated Plexiform Neurofibromas: With Ignacio Blanco, MD, PhD 6:32

2M ago6:32

6:32

In our exclusive interview, Dr Blanco discussed the significance of this regulatory milestone for a population that has historically lacked effective medical options. He reviewed the pivotal phase 2b ReNeu clinial trial (NCT03962543)that supported this decision, which enrolled both adult and pediatric patients with nonresectable PNs and evaluated c…

1
S13 Ep40: The Role of Combination Checkpoint Blockade Is Evolving in MSI-H mCRC: With Elena Élez, MD, PhD 10:44

2M ago10:44

10:44

In our exclusive interview, Dr Élez discussed recent data comparing nivolumab (Opdivo) monotherapy with nivolumab plus ipilimumab (Yervoy) across multiple lines of therapy in patients with MSI-H mCRC. She detailed efficacy and quality‑of‑life outcomes, noting that the combination appeared to offer enhanced clinical benefit without a negative effect…

1
S13 Ep39: Efficacy of Immune Checkpoint Inhibition in Oncology May Translate to Neurologic Disorders: With Shailee S. Shah, MD 17:30

2M ago17:30

17:30

In today’s OncClub episode, we had the pleasure of speaking with Shailee S. Shah, MD, about a retrospective study she and colleagues conducted to understand the effect of immune checkpoint inhibitors on patients with cancer and pre-existing neurologic autoimmune diseases, including multiple sclerosis, myasthenia gravis, Guillain-Barre syndrome, and…

1
S13 Ep38: Guideline Updates and Trial Data Solidify the Role of HER2/MET IHC Testing in NSCLC: With Martin F. Dietrich, MD, PhD 26:08

2M ago26:08

26:08

In today’s episode, we had the pleasure of speaking with Martin F. Dietrich, MD, PhD, about updates and best practices for HER2 and MET immunohistochemistry (IHC) testing for patients with non–small cell lung cancer (NSCLC). Dr Dietrich is a medical oncologist at Cancer Care Centers of Brevard in Rockledge, Florida; as well as an assistant professo…

1
Beautifully Broken with Maggie Fanara 37:56

2M ago37:56

37:56

Show Notes: On this episode, we sit down with donor mom and author Maggie Fanara, whose debut book is titled Beautifully Broken. Maggie opens up about the lies she once believed about herself, and how God met her in the depths of abuse, heartbreak, and loss to rewrite her story. Maggie invites us into her journey of healing and purpose where she di…

1
S13 Ep37: Retrospective Data Highlight Improved Efficacy With Maintenance Therapy vs Treatment Breaks in mCRC: With Connie Lai, MD 5:04

2M ago5:04

5:04

In today’s episode, we had the pleasure of speaking with Connie Lai, MD, a medical oncology resident at Queen Elizabeth Hospital in Hong Kong, about a retrospective, dual-center study examining post-induction treatment strategies in metastatic colorectal cancer (mCRC).By OncLive® On Air

1
S13 Ep36: CRISPR-Edited CISH Knockout TIL Therapy Paves Novel Treatment Paths in CRC: With Branden Moriarity, PhD; and Beau Webber, PhD 15:17

2M ago15:17

15:17

In today’s OncClub episode, we had the pleasure of speaking with Branden Moriarity, PhD; and Beau Webber, PhD, about a study evaluating neoantigen-reactive CISH knockout tumor-infiltrating lymphocyte (TIL) therapy in patients with metastatic gastrointestinal cancers. Dr Moriarity is an associate professor in the Division of Pediatric Hematology/Onc…

1
S13 Ep35: Telisotuzumab Vedotin Represents a New Treatment Development for c-Met–Overexpressing NSCLC: With Joshua K. Sabari, MD 9:59

2M ago9:59

9:59

In today’s episode, we spoke with Joshua K. Sabari, MD, about the use of telisotuzumab vedotin-tllv (Emrelis) in patients with c-MET–overexpressing, nonsquamous, EGFR wild-type advanced non–small cell lung cancer (NSCLC). Dr Sabari is an assistant professor in the Department of Medicine at the New York University Grossman School of Medicine; as wel…

1
S13 Ep34: Cortes’ Journey Helps Reshape Hematologic Cancer Care: With Girindra Raval, MD; and Jorge Cortes, MD 45:46

2M ago45:46

45:46

Cancer, Character, and Calling: The Oncologist's Journey, hosted by Girindra Raval, MD, is a podcast highlighting how top oncologists have navigated the field over the course of their careers, the passion that drove them to enter the oncology space, and the ongoing work that will continue to transform cancer care. Each episode, Raval will welcome a…

1
S13 Ep33: Isatuximab-Based Triplet Delivered via On-Body System Shows Promise in RRMM: With Xavier Leleu, MD, PhD; and Beth Faiman, PhD, MSN, APN-BC 21:40

2M ago21:40

21:40

In our exclusive interview, Drs Leleu and Faiman discussed the unique methods and design of IRAKLIA, key efficacy and safety findings from this trial, and the benefits of using on-body delivery systems to deliver effective therapies to patients in more convenient and patient-centered ways.By OncLive® On Air

1
S13 Ep32: European Approval of Zanidatamab Expands Treatment Options for HER2+ Biliary Tract Cancer: With Arndt Vogel, MD 11:54

3M ago11:54

11:54

In today’s episode, we had the opportunity to speak with Arndt Vogel, MD, about the European Commission’s (EC's) July 2025 marketing authorization of zanidatamab-hrii (Ziihera) for the treatment of adult patients with previously treated, unresectable, locally advanced or metastatic HER2-positive biliary tract cancer. Dr Vogel is a faculty member at…

1
S13 Ep31: IHC Testing Leads to Early Detection of TP53-Mutant AML and MDS: With Jonathan M. Gerber, MD; and Shyam A. Patel, MD, PhD 28:45

3M ago28:45

28:45

In today’s episode, we had the pleasure of speaking with Jonathan M. Gerber, MD; and Shyam A. Patel, MD, PhD, about a study they conducted investigating the use of immunohistochemistry (IHC) as a biomarker for early TP53 mutation identification in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). Dr Gerber is a member …